These courses are intended for internal hospital staff.
Activity Description:
This series focuses on a multidisciplinary team approach to care is fostered through peer-to-peer discussion and collaboration. The team diagnosis and treatment, includes radiological, pathological findings and immunohistochemical testing, bridges these gaps across the continuum of care in order to enhance the overall quality of patient-centered breast cancer care.
TARGET AUDIENCE:
Medical Oncologists, Radiation Oncologists, Breast Cancer Surgeons, General Surgeons, Pathologists, Radiologists, Gynecologists, Nurses, Patient Care Facilitators and all personnel involved in the care of the breast cancer patient.
LEARNING OBJECTIVES:
- Implement optimal course of treatment for breast cancer patients.
- Utilize multiple disciplinary approaches to diagnosis and treatment options, including radiological findings, pathological findings and immunohistochemical testing.
- Determine cancer staging using various breast imaging modalities.
- Promote a multidisciplinary team approach by bridging gaps across the continuum of care in order to enhance the overall quality of patient-centered breast cancer care.
MODERATOR:
Therese Cusick, MD
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Accreditation:
The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support:
This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.
Disclosure:
The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.